BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC
743 results:

  • 1. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
    D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
    Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.
    Santoro A; Bragantini E; Castiglione F; Ganesan R; Matias-Guiu X; Frattini M; Gallotta V; Garcia P; Pattni Y; Tsiampali-Laprell J; Bisaro B; Barbareschi M; Zannoni GF;
    Pathologica; 2024 Feb; 116(1):32-45. PubMed ID: 38482673
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of mlh1 p.L582H.
    Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
    Liu YL; Weigelt B
    Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Khushman MM; Toboni MD; Xiu J; Manne U; Farrell A; Lou E; Shields AF; Philip PA; Salem ME; Abraham J; Spetzler D; Marshall J; Jayachandran P; Hall MJ; Lenz HJ; Sahin IH; Seeber A; Powell MA
    Clin Cancer Res; 2024 May; 30(9):1906-1915. PubMed ID: 38350001
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
    Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
    Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Next-generation sequencing and immunohistochemistry approaches for microsatellite instability detection in endometrial cancer.
    Ali AS; Alalem LS
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):237-242. PubMed ID: 38279425
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
    Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
    JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.
    Addante F; d'Amati A; Santoro A; Angelico G; Inzani F; Arciuolo D; Travaglino A; Raffone A; D'Alessandris N; Scaglione G; Valente M; Tinnirello G; Sfregola S; Padial Urtueta B; Piermattei A; Cianfrini F; Mulè A; Bragantini E; Zannoni GF
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256131
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. New Insights into Lynch Syndrome: A Narrative Review.
    Ene CV; Bulai CTLA; Geavlete P; Popescu RI; Vacaroiu IA; Georgescu DE; Isaconi IV; Munteanu MDLA; Ene CD; Militaru A; Geavlete B; Multescu R
    Chirurgia (Bucur); 2023 Dec; 118(6):584-595. PubMed ID: 38228591
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to mlh1 Promoter Hypermethylation.
    Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
    Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
    Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
    Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
    Keyhanian K; Han L; Howitt BE; Longacre T
    Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. mlh1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
    Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
    J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
    [TBL] [Abstract] [Full Text] [Related]  

  • 15.
    Carnevali IW; Cini G; Libera L; Sahnane N; Facchi S; Viel A; Sessa F; Tibiletti MG
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003003
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
    Li M; Zheng W
    Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
    Xing B; Zhang X; Gu X; Xiang L; Wang C; Jin Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17529-17541. PubMed ID: 37906351
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in uterine Endometrioid Carcinoma.
    Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
    Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]    [Full Text] [Related]  

  • 20. Comparison of Methods for Testing Mismatch Repair Status in Endometrial cancer.
    Mendiola M; Heredia-Soto V; Ruz-Caracuel I; Baillo A; Ramon-Patino JL; Escudero FJ; Miguel M; Pelaez-Garcia A; Hernandez A; Feliu J; Hardisson D; Redondo A
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833916
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 38.